A Phase 3 interventional study of Levetiracetam (LEV) in Epilepsy and Partial Onset Seizures, sponsored by UCB Japan Co. Ltd.. Completed at 27 sites in Japan. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2015-12-31.
Sponsored by UCB Japan Co. Ltd. (part of UCB S.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies testing levetiracetam in Epilepsy — 4 open to participants now, 4 under way, 2 of them phase 3. Levetiracetam · Epilepsy.
Among the 60 studies testing levetiracetam in Epilepsy, this one is the 33rd largest by enrollment, is one of 5 that started in 2011, is one of 28 in phase 3, and was the 46th registered.
1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.
Browse Epilepsy studies →4 of the 60 studies testing levetiracetam in Epilepsy are open now, in 3 countries. Recruiting first, the newest first:
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Sites in Spain
Ages 40+
Waad Alkathiri · Sites in Saudi Arabia
Ages 18+
Xiangya Hospital of Central South University · Sites in China
Ages 18–80
National Taiwan University Hospital
Ages 20+
By country, each count listing its studies:
Levetiracetam: first FDA approval 1999 (KEPPRA), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 13 · Phase 3 28 · Phase 4 13
First in 1998; this study’s year is marked. 5 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 71 is above the median of 50 across 1,239 interventional studies indexed under Epilepsy.
Median enrollment 94 across the 60 interventional studies. Of the 55 that completed or were terminated, 31 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 60 have an industry lead sponsor. The 10 most frequent:
This study is registered under UCB Japan Co. Ltd., one of the names counted as UCB S.A.. Under that name alone:
UCB Japan Co. Ltd. is the lead sponsor of 14 studies on the registry; none are open to participants now.
128 studies in Epilepsy by UCB S.A.: 2 open now, 2 under way, 2 of them phase 3. Of 121 finished, 90 (74%) have results posted.
Among the 128 studies in Epilepsy by UCB S.A., this one is the 69th largest by enrollment of the 116 interventional ones that give a count, is one of 13 that started in 2011, is one of 74 in phase 3, and was the 82nd registered.
UCB S.A.’s Epilepsy studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 60 studies testing levetiracetam in Epilepsy, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 128 in Epilepsy:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy of Levetiracetam (LEV) used as monotherapy, with efficacy measured as 6-month seizure freedom at the last evaluated dose in the LEV 1000 mg/day to 2000 mg/day group, in newly or recently diagnosed epilepsy subjects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects in the LEV 1000 mg/day to 2000 mg/day group receive the initial dose of LEV 1000 mg/day for the 1- week Stabilization Period and enter the Evaluation Period. Unless a seizure occurs during the Evaluation Period, the subjects will continue LEV 1000 mg/day for 26 weeks. If a seizure occurs during the Evaluation Period, the dose will be increased to 2000 mg/day and a restart of stabilization on LEV 2000 mg/day for 1 week is required prior to restarting the 26-weeks Evaluation Period on LEV 2000 mg/day. The LEV dose could be decreased as a fallback option at the investigator's discretion, if the subject did not tolerate the LEV dosage, as evidenced by the development of an AE. The fallback option was permitted to be performed once for subjects on LEV 2000 mg/day at any time during the restarted Stabilization Period (SP), restarted Evaluation Period (EP), or Maintenance Period (MP), as well as for subjects on LEV 3000 mg/day at any time during the SP, EP, or MP.
Drug: Levetiracetam (LEV)
Unless a seizure occurs, the subjects in this arm will continue LEV 3000 mg/day for 26 weeks. Subjects in the LEV 3000 mg/day group undergo a 4-week Up-Titration Period prior to the 1-week Stabilization Period. They receive 1000 mg/day for 2 weeks and 2000 mg/day for 2 weeks during the Up-Titration Period and LEV 3000 mg/day for 1 week during the Stabilization Period. The LEV dose could be decreased as a fallback option at the investigator's discretion, if the subject did not tolerate the LEV dosage, as evidenced by the development of an AE. The fallback option was permitted to be performed once for subjects on LEV 2000 mg/day at any time during the restarted Stabilization Period (SP), restarted Evaluation Period (EP), or Maintenance Period (MP), as well as for subjects on LEV 3000 mg/day at any time during the SP, EP, or MP.
Drug: Levetiracetam (LEV)
* Active Substance: Levetiracetam * Pharmaceutical Form: Film-coated tablet * Concentration: LEV 250 mg, LEV 500 mg * Frequency: Twice daily * Route of Administration: Oral use
Also known as: Keppra, E Keppra
Percentage of Subjects in the Levetiracetam (LEV) 1000 mg/Day to 2000 mg/Day Group Who Are Seizure Free for 26 Consecutive Weeks of Treatment During the Evaluation Period
A subject was considered seizure free, if no seizure occurred during the 6 consecutive months (26 weeks) in the Evaluation Period. If one of the following occurred, the subject was not considered seizure free: * A documented seizure during 6 consecutive months of the Evaluation Analysis Period * Subject discontinued the study prematurely during the Evaluation Analysis Period * Missing Seizure Count Case Report Forms (CRFs) prior to completing the Evaluation Analysis Period.
Time frame: From the end of the 1-week Stabilization Period over the 26-weeks Evaluation Period
Percentage of Subjects in the Levetiracetam (LEV) 1000 mg/Day to 2000 mg/Day Group Who Are Seizure Free for 52 Consecutive Weeks of Treatment During the Evaluation Period and the Maintenance Period
Subjects who complete the 26-weeks Evaluation Period without having a seizure will continue receiving the same dose of LEV as in the Evaluation Period during the 26-weeks Maintenance Period unless a seizure occurs.
Time frame: From entry in the 26-weeks Evaluation Period to the end of the 26-weeks Maintenance Period
Percentage of Subjects in the Levetiracetam (LEV) 3000 mg/Day Group Who Are Seizure Free for 26 Consecutive Weeks of Treatment During the Evaluation Period
A subject was considered seizure free, if no seizure occurred during the 6 consecutive months (26 weeks) in the Evaluation Period. If one of the following occurred, the subject was not considered seizure free: * A documented seizure during 6 consecutive months of the Evaluation Analysis Period * Subject discontinued the study prematurely during the Evaluation Analysis Period * Missing Seizure Count Case Report Forms (CRFs) prior to completing the Evaluation Analysis Period.
Time frame: From the end of the 1-week Stabilization Period over the 26-weeks Evaluation Period
Percentage of Subjects in the Levetiracetam (LEV) 3000 mg/Day Group Who Are Seizure Free for 52 Consecutive Weeks of Treatment During the Evaluation Period and the Maintenance Period
Subjects who complete the 26-weeks Evaluation Period without having a seizure will continue receiving LEV 3000 mg/day during the 26-weeks Maintenance Period unless a seizure occurs.
Time frame: From entry in the 26-weeks Evaluation Period to the end of the 26-weeks Maintenance Period
Time to First Seizure at the Last Evaluated Dose in Subjects in the Levetiracetam (LEV) 1000 mg/Day to 2000 mg/Day Group
Time was measured from first day of last evaluated dose. Seizures during Stabilization were not considered. The Median time to first seizure will be estimated from the Kaplan-Meier curve.
Time frame: During Evaluation, Maintenance and Safety Follow Up Period after 1-week Stabilization Period, assessed up to 1 year
Time to Withdrawal at the Last Evaluated Dose in Subjects in the Levetiracetam (LEV) 1000 mg/Day to 2000 mg/Day Group
Median time to withdrawal will be estimated from the Kaplan-Meier curve.
Time frame: During 1-week Stabilization Period, Evaluation, Maintenance and Safety Follow Up Period, assessed up to 1 year
Time to First Seizure in Subjects in the Levetiracetam (LEV) 3000 mg/Day Group
Time was measured from first day of last evaluated dose. Seizures during Stabilization were not considered. The Median time to first seizure will be estimated from the Kaplan-Meier curve.
Time frame: During Evaluation, Maintenance and Safety Follow Up Period after 1-week Stabilization Period, assessed up to 1 year
Time to Withdrawal in Subjects in the Levetiracetam (LEV) 3000 mg/Day Group
Median time to withdrawal will be estimated from the Kaplan-Meier curve.
Time frame: During 1-week Stabilization Period, Evaluation, Maintenance and Safety Follow Up Period, assessed up to 1 year
This multicenter study started to enroll subjects in December 2011 in order to end up with 27 centers with enrolled subjects in Japan.
| Milestone | Levetiracetam 1000 mg/Day to 2000 mg/Day Group | Levetiracetam 3000 mg/Day Group |
|---|---|---|
| Started | 61 | 10 |
| Completed | 39 | 3 |
| Not completed | 22 | 7 |
| Withdrew: Lack of efficacy | 4 | 3 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Withdrawal by subject | 9 | 3 |
| Withdrew: Sae, non-fatal | 2 | 0 |
| Withdrew: Ae, non-serious non-fatal | 3 | 1 |
| Withdrew: Sae,non-fatal+ae,non-serious non-fatal | 1 | 0 |
| Withdrew: Other reason | 2 | 0 |
A subject was considered seizure free, if no seizure occurred during the 6 consecutive months (26 weeks) in the Evaluation Period. If one of the following occurred, the subject was not considered seizure free: * A documented seizure during 6 consecutive months of the Evaluation Analysis Period * Subject discontinued the study prematurely during the Evaluation Analysis Period * Missing Seizure Count Case Report Forms (CRFs) prior to completing the Evaluation Analysis Period.
| percentage of participants | Levetiracetam 1000 mg/Day to 2000 mg/Day Group |
|---|---|
| Percentage of Subjects in the Levetiracetam (LEV) 1000 mg/Day to 2000 mg/Day Group Who Are Seizure Free for 26 Consecutive Weeks of Treatment During the Evaluation Period | 73.8 (60.9 to 84.2) |
Subjects who complete the 26-weeks Evaluation Period without having a seizure will continue receiving the same dose of LEV as in the Evaluation Period during the 26-weeks Maintenance Period unless a seizure occurs.
| percentage of participants | Full Analysis Set (LEV 1000 mg/Day to 2000 mg/Day Group) |
|---|---|
| Percentage of Subjects in the Levetiracetam (LEV) 1000 mg/Day to 2000 mg/Day Group Who Are Seizure Free for 52 Consecutive Weeks of Treatment During the Evaluation Period and the Maintenance Period | 59.0 (45.7 to 71.4) |
A subject was considered seizure free, if no seizure occurred during the 6 consecutive months (26 weeks) in the Evaluation Period. If one of the following occurred, the subject was not considered seizure free: * A documented seizure during 6 consecutive months of the Evaluation Analysis Period * Subject discontinued the study prematurely during the Evaluation Analysis Period * Missing Seizure Count Case Report Forms (CRFs) prior to completing the Evaluation Analysis Period.
| percentage of participants | Levetiracetam 3000 mg/Day Group |
|---|---|
| Percentage of Subjects in the Levetiracetam (LEV) 3000 mg/Day Group Who Are Seizure Free for 26 Consecutive Weeks of Treatment During the Evaluation Period | 22.2 (2.8 to 60.0) |
Subjects who complete the 26-weeks Evaluation Period without having a seizure will continue receiving LEV 3000 mg/day during the 26-weeks Maintenance Period unless a seizure occurs.
| percentage of participants | Full Analysis Set (LEV 3000 mg/Day Group) |
|---|---|
| Percentage of Subjects in the Levetiracetam (LEV) 3000 mg/Day Group Who Are Seizure Free for 52 Consecutive Weeks of Treatment During the Evaluation Period and the Maintenance Period | 11.1 (0.3 to 48.2) |
Time was measured from first day of last evaluated dose. Seizures during Stabilization were not considered. The Median time to first seizure will be estimated from the Kaplan-Meier curve.
| days | Full Analysis Set (LEV 1000 mg/Day to 2000 mg/Day Group) |
|---|---|
| Time to First Seizure at the Last Evaluated Dose in Subjects in the Levetiracetam (LEV) 1000 mg/Day to 2000 mg/Day Group | NA (359 to NA) |
Median time to withdrawal will be estimated from the Kaplan-Meier curve.
| days | Full Analysis Set (LEV 1000 mg/Day to 2000 mg/Day Group) |
|---|---|
| Time to Withdrawal at the Last Evaluated Dose in Subjects in the Levetiracetam (LEV) 1000 mg/Day to 2000 mg/Day Group | NA (NA to NA) |
Time was measured from first day of last evaluated dose. Seizures during Stabilization were not considered. The Median time to first seizure will be estimated from the Kaplan-Meier curve.
| days | Full Analysis Set (LEV 3000 mg/Day Group) |
|---|---|
| Time to First Seizure in Subjects in the Levetiracetam (LEV) 3000 mg/Day Group | 106 (9 to NA) |
Median time to withdrawal will be estimated from the Kaplan-Meier curve.
| days | Levetiracetam 3000 mg/Day Group |
|---|---|
| Time to Withdrawal in Subjects in the Levetiracetam (LEV) 3000 mg/Day Group | 91 (21 to 197) |
Collected over Treatment-emergent Adverse Events were collected from Screening (Week 0) over the Evaluation and Maintenance Period (Week 4 to Week 53) until the last Follow-up Visit or Withdrawal Visit.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Levetiracetam 1000 mg/Day to 2000 mg/Day Group | — | 8/61 (13.1%) | 58/61 (95.1%) |
| Levetiracetam 3000 mg/Day Group | — | 2/10 (20%) | 10/10 (100%) |
| Event | Levetiracetam 1000 mg/Day to 2000 mg/Day Group | Levetiracetam 3000 mg/Day Group |
|---|---|---|
| EpilepsyNervous system disorders | 0/61 | 1/10 |
| Meniscus removalSurgical and medical procedures | 0/61 | 1/10 |
| Status epilepticusNervous system disorders | 3/61 | 0/10 |
| Postictal stateNervous system disorders | 2/61 | 0/10 |
| IrritabilityGeneral disorders | 1/61 | 0/10 |
| Anaphylactic reactionImmune system disorders | 1/61 | 0/10 |
| CystitisInfections and infestations | 1/61 | 0/10 |
| Kaposi's varicelliform eruptionInfections and infestations | 1/61 | 0/10 |
| PyelonephritisInfections and infestations | 1/61 | 0/10 |
| ConvulsionNervous system disorders | 1/61 | 0/10 |
| Event | Levetiracetam 1000 mg/Day to 2000 mg/Day Group | Levetiracetam 3000 mg/Day Group |
|---|---|---|
| NasopharyngitisInfections and infestations | 47/61 | 4/10 |
| SomnolenceNervous system disorders | 25/61 | 2/10 |
| DiarrhoeaGastrointestinal disorders | 8/61 | 2/10 |
| Head injuryInjury, poisoning and procedural complications | 1/61 | 2/10 |
| Weight increasedInvestigations | 2/61 | 2/10 |
| MalaiseGeneral disorders | 12/61 | 0/10 |
| HeadacheNervous system disorders | 10/61 | 1/10 |
| DizzinessNervous system disorders | 8/61 | 1/10 |
| InfluenzaInfections and infestations | 7/61 | 0/10 |
| VertigoEar and labyrinth disorders | 0/61 | 1/10 |
Baseline Characteristics refer to the Safety Set (SS). SS consists of all subjects in the Enrolled Set, who received at least 1 dose of the Investigational Medicinal Product (IMP).
| Age, Categorical(Participants) | Levetiracetam 1000 mg/Day to 2000 mg/Day Group | Levetiracetam 3000 mg/Day Group | Total Title |
|---|---|---|---|
| <=18 years | 10 | 1 | 11 |
| Between 18 and 65 years | 45 | 8 | 53 |
| >=65 years | 6 | 1 | 7 |
| Age, Continuous(years) | Levetiracetam 1000 mg/Day to 2000 mg/Day Group | Levetiracetam 3000 mg/Day Group | Total Title |
|---|---|---|---|
| Mean | 36.5 ± 18.0 | 37.0 ± 18.6 | 36.5 ± 17.9 |
| Sex: Female, Male(Participants) | Levetiracetam 1000 mg/Day to 2000 mg/Day Group | Levetiracetam 3000 mg/Day Group | Total Title |
|---|---|---|---|
| Female | 34 | 4 | 38 |
| Male | 27 | 6 | 33 |
| Region of Enrollment(participants) | Levetiracetam 1000 mg/Day to 2000 mg/Day Group | Levetiracetam 3000 mg/Day Group | Total Title |
|---|---|---|---|
| Japan | 61 | 10 | 71 |
| Weight(kilogram (kg)) | Levetiracetam 1000 mg/Day to 2000 mg/Day Group | Levetiracetam 3000 mg/Day Group | Total Title |
|---|---|---|---|
| Mean | 58.98 ± 12.30 | 62.58 ± 15.11 | 59.48 ± 12.67 |
| Height(centimeter (cm)) | Levetiracetam 1000 mg/Day to 2000 mg/Day Group | Levetiracetam 3000 mg/Day Group | Total Title |
|---|---|---|---|
| Mean | 161.96 ± 8.77 | 166.07 ± 10.21 | 162.54 ± 9.02 |
The record gives a start of Dec 2011, a primary completion of Oct 2013 and a completion of Apr 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2014, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Levetiracetam